Novel innate immunity factor inhibits HIV infection by targeting lipid rafts, study finds

Novel innate immunity factor inhibits HIV infection by targeting lipid rafts, study finds

State-purchased insurance plans improve HIV outcomes, save healthcare costs Host cell lipid rafts -- subdomains of the plasma membrane that contain high concentrations of cholesterol and glycosphingolipids -- are critically important for the biology of HIV and are involved in HIV-1 assembly and budding and the infection of target cells. Given the dependence HIV has on lipid rafts, and AIBP's ability to reduce them, the researchers hypothesized that AIBP could inhibit HIV replication. The results of the study show that exogenously added AIBP reduced the abundance of lipid rafts and inhibited HIV replication in vitro and in vivo, while knockdown of AIBP native to the cells increased HIV replication. With these findings, the authors suggest that new therapeutic approaches aimed at inhibition of HIV infection and HIV-associated comorbidities via stimulation of AIBP production can be envisioned. "Through this study, we identified a novel innate immunity factor that inhibits HIV infection by targeting lipid rafts," Bukrinsky said. "Further studies could possibly show AIBP may also protect against infection by other viruses and microbes." Source: George Washington University Journal reference: Dubrovsky, L., et al. (2020) Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts. mBio . doi.org/10.1128/mBio.02956-19 .



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More